Presentation is loading. Please wait.

Presentation is loading. Please wait.

Peptic ulcer disease. Disruption of mucosal and submucosal integrity of the stomach and/or duodenum >5 mm in size Definition.

Similar presentations


Presentation on theme: "Peptic ulcer disease. Disruption of mucosal and submucosal integrity of the stomach and/or duodenum >5 mm in size Definition."— Presentation transcript:

1 peptic ulcer disease

2 Disruption of mucosal and submucosal integrity of the stomach and/or duodenum >5 mm in size Definition

3 Epidemiology Peptic ulcer disease Prevalence: 12% of men and 10% of women in U.S.  Duodenal ulcers  6–15% of the Western population  Gastric ulcers  Less common than DU  occur later in life than DU; peak in 6 decade  More than half occur in males

4 Epidemiology Helicobacter pylori infection  Prevalence :  30% in U.S.  10% of Americans < 30 years  80% in developing parts of the world

5 Risk Factors  Genetic predisposition  First-degree relatives of patients with DU or GU are at 3-fold increased risk for ulcer  Patients with blood group O may be at increased risk; the antigen may be a target of H. pylori.

6 Risk Factors  Psychological stress  Evidence for causal effect is mainly anecdotal.  Increased numbers of stressful events do not distinguish patients with DU from those without DU.

7 Risk factors for H. pylori  Birth or residence in a developing country  Domestic crowding  Unsanitary living conditions  Unclean food or water  Exposure to gastric contents  Poor socioeconomic status  Less education

8 Risk factors for NSAID-induced PUD  Advanced age  History of ulcer  Concomitant use of glucocorticoids or anticoagulants  High-dose NSAIDs  Multiple NSAIDs use  Serious or multisystem disease  Concomitant infection with H. pylori  Cigarette smoking  Alcohol consumption

9 Cigarette smoking  Increase duodenal acid by:  Increasing gastric acid secretion  Impair duodenal and pancreatic bicarbonate  Smokers are at increased risk for DU and GU

10 Smoking in Hp-associated PUD is major risk factor for:  Occurrence  Persistence  Recurrence following Hp eradication  Complications  Impairs ulcer healing  Increases the need for surgery

11 Etiology of PUD

12 Disease Associated with PUD  COPD  CRF  Cirrhosis  Organ transplant  Nephrolithiasis  α1 antitrypsin deficiency  Hyperparathyroidism  Systemic mastocytosis  Coronary artery disease  Polycythemia vera  Chronic pancreatitis

13 Symptoms of PUD

14 Laboratory evaluation  Routine laboratory studies are typically normal.  Screening studies should include :  CBC  liver chemistries  serum creatinine  serum calcium.  A fasting serum gastrin level is indicated in ulcers refractory to therapy, with a positive family history, or in cases requiring surgery.

15

16

17

18

19 ASGE Guidelines for endoscopy indication in dyspeptic patients 1.New-onset dyspepsia in older than age Alarm features in any age that suggest significant structural disease or malignancy. 3. Persistent dyspeptic symptoms

20 Alarm features  Family history of upper GI malignancy  Weight loss  Overt GI bleeding, iron deficiency anemia  Progressive dysphagia or odynophagia  Persistent vomiting  Palpable mass  Lymphadenopathy.

21 Dyspeptic patients younger than 50 without alarm features  Should be test for H. pylori  If positive : H.pylori eradication  If negative :  short trial (4-8 weeks) PPI or  EGD  NSAID stopped, if possible.

22 Endoscopy in DU (ASGE RECOMMENDATIONS)  Endoscopy is not recommended in benign-appearing, uncomplicated duodenal ulcers identified on radiologic imaging  DU are extremely unlikely malignant, and routine biopsy is not recommended

23

24 Endoscopy in GU (ASGE RECOMMENDATIONS)  Patients diagnosed with GU via radiologic imaging should undergo endoscopy.  Although the presence of concurrent DU supports the diagnosis of a benign gastric ulcer, these radiologic criteria are not reliable.

25

26 Endoscopy in GU  If a radiologic benign-appearing GU respond to medical therapy and has no alarm features, is reasonable to a medical therapy course for 8-12 weeks before an endoscopy.  If has not healed within that period, at least four jumbo biopsies or seven regular biopsies should be obtained.

27 GU

28 HEALED ULCER

29 Biopsy in GU  Biopsy of all gastric ulcers was recommended in the past because older data suggested that 5% to 11% of GU represented malignancy  There are no recent data to recommend the need for biopsy of all GU.

30 Routine biopsy may not be necessary in GU If history suggest a very low risk of malignancy  In young patient taking NSAIDs and endoscopic typical NSAID lesions (eg, shallow flat antral ulcer with associated erosions) biopsy is not necessary.

31 Role of endoscopic surveillance in DU  Is not recommended if symptoms resolve after a course of acid suppression with H Pylori eradication and discontinuation of NSAID.  Is recommended in persistent symptoms for  Rule out refractory peptic ulcers  Rule out ulcers with nonpeptic etiologies

32 surveillance endoscopy in GU May be unnecessary:  When history suggest a low risk of cancer (eg, a young patient taking NSAIDs with endoscopic appearance of typical NSAID-associated lesions)  In benign GU on EGD and biopsy with a defined etiology (eg, NSAID or H Pylori ) that is asymptomatic after a course of therapy

33 Surveillance EGD indication in GU 1. Endoscopically suspicious for malignancy, even if biopsy samples are benign. 2.Symptomatic despite an appropriate therapy and previous benign biopsy(for detect refractory, benign nonpeptic etiologies and occult malignancy) 3.Those did not biopsied at index EGD for any reason ( active GIB,coagulopathy, patien instability) 4. Gastric ulcers without a clear etiology

34 ASGE Recommendations in PUD 1. H Pylori testing should be performed in all PUD because it is a common etiology. 2. DU is extremely unlikely to be malignant, and routine biopsy is not recommended. 3. EGD is not recommended in benign-appearing, uncomplicated DU identified on radiologic imaging.

35 ASGE recommendation cont. 4. Surveillance EGD be considered in DU with persistent symptoms. 5.Most GU need biopsy because malignant GU may appear benign in EGD. However, in young patients taking NSAIDs with multiple benign-appearing GU, malignancy is very low. Therefore, biopsy and surveillance endoscopy should be individualized.

36 ASGE recommendation cont. 6. Surveillance endoscopy indication in GU:  Symptomatic despite a medical therapy.  Ulcer without a clear etiology  If biopsy was not obtained at the index EGD. 7. In refractory PUD, surveillance endoscopy should be performed until the ulcer has healed or the etiology has been defined.

37 ASGE recommendation cont. 8. Endoscopy should be performed early in the course of hospitalization in bleeding PUD 9. In rebleeding after initial endoscopic hemostasis, repeat endoscopic therapy is recommended before considering surgical or radiologic intervention. 10. Endoscopy is not recommend in clinical evidence of acute perforation.

38 ASGE recommendation cont. 11. Endoscopy recommended for evaluation of gastric outlet obstruction. 12. Endoscopic balloon dilation be considered for the management of benign gastric outlet obstruction.

39 Giant ulcers (>2cm)  patients with giant ulcers tend to be older and may present with atypical symptoms including anorexia and weight loss.  Is aggressive disease, with a higher incidence of bleeding, penetration, perforation, mortality rates, and greater need for urgent surgery

40

41 Rol of EGD in giant ulcer 1. EGD is important for the diagnosis of giant GU because barium studies may miss these ulcers due to their large, shallow craters 2.Ruling out malignancy, Crohn's, eosinophilic gastroenteritis 3.Surveillance and documentation of healing

42 prepyloric ulcers Distal antral ulcers, especially 2 to 3 cm of the pylorus:  Heal more slowly  Recur more likely

43 Refractory ulcers  Fail to heal despite 8 to 12 weeks of PPI  Surveillance EGD should be considered until:  Healing is documented or  Etiology is defined (eg, surreptitious NSAID use, high gastrin states, ischemia).  Surgical consultation may be considered for persistent nonhealing PUD.

44 Upper gastrointestinal radiography  Barium within an ulcer niche, (round or oval ; by smooth edema).  Folds radiating to the crater, and deformities in the region secondary to spasm, edema, and scarring.  Radiographic signs suggesting gastric malignancy : (1) Ulcer within a definitive mass (2) Fused, or nodular mucosal folds as they approach the margin of the crater (3) Irregular filling defects in ulcer crater

45

46 CT Scan Spiral and multislice contrast CT is clearly the most valuable test for penetrating or perforated ulcer  Free air  Fluid collections  Inflammatory changes in surrounding soft tissues  Extravasation or sinus tracks  Localizing the site of perforation or penetration

47 AGA Guideline on the Management of H. pylori Infection  H. pylori Infection is one of the most common worldwide human infections  Is associated with a number of important upper GI conditions :  Chronic gastritis  Peptic ulcer disease  Gastric malignancy.

48 DIAGNOSING AND TREATING H.PYLORI CLEAR INDICATIONS ? CONTROVERSY ?

49 Clear indication for H.P test-and-treat 1. Active peptic ulcer disease 2. Past history of documented peptic ulcer 3. Gastric MALT lymphoma. 4. Uninvestigated dyspepsia in:  Under the age of 55 yr and no “alarm features”

50 Contraversy indication for H.P test-and-treat  Functional dyspepsia  Small but significant clinical benefit from H.pylori eradication.  GERD  H. pylori eradication not worsens nor improves GERD symptoms.  Treatment of H. pylori should not be withheld related to concerns of creating or worsening of GERD

51 Contraversy indication for H.P test-and- treat  NSAIDs  Regardless of NSAID, all patients with a PUD should be tested and treated for H.pylori.  Iron deficiency  Data support an association but do not prove cause and effect.

52 Contraversy indication for H.P test- and-treat  Gastric adenocarcinoma  Curing H. pylori may prevent progression of metaplasia to gastric adenocarcinoma, there is no definitive population based data

53 Diagnosting tests for H.pylori  Endoscopic: 1.Rapid urease test 2.Histology 3.Culture  Non endoscopic: 1.Sreology 2.Urese breath test 3.Fecal antigen test

54 Rapid urease test (RUT)  Base: PH↑ due to H. pylori urease  Biopsy for RUT should be done from two site  Sensitivity>90% and specificity >95%  Acute ulcer bleeding at the time of testing may decrease the sensitivity

55 False negative RUT  Unfortunately, most patients referred for EGD are taking PPI or have recently received antibiotics or bismuth.  This cause 20% False negative RUT

56 What is your plan after a negative RUT?  histology of same RUT biopsies Or  UBT or FAT at a later date

57 Histology for H.pylori  Is imperfect gold standard because detection of H. pylori is related to site, number and size of gastric biopsies  Three biopsies must be obtained: 1. One from anglularis 2. One from greater curvature of corpus 3. One from greater curvature of antrum  Sensitivity and specificity >95%

58 Antibody Tests  Is present 21 days after infection and remain long after eradication  Only IgG is recomended  Poor PPV limits its usefulness in clinical practice in low prevalence area.

59 Urea Breath Tests(UBT)  C 13 /C 14 labeled urea  labeled CO 2  C 14 UBT is safe. but C 13 test is preferred in children and pregnancy  Sensitivity and specificity exceeding 95%  Accurate in post treatment eradication

60 Recommendation prior to the UBT 1.DC bismuth and antibiotics for 28 days 2.DC PPI for 7–14 days 3.DC H2RA for 24–48 hour before the UBT Antacids do not affect the accuracy of UBT

61 Fecal Antigen Test (FAT)  Is approved by the FDA for:  H.pylory infection screening  Establishing cure following therapy(more than 4 or perhaps 8–12 wk after treatment)  Sensitivity is reduced by recent use of bismuth antibiotics, and PPI  Specificity is reduced in the setting of GIB

62 H.pylory tests in acute upper GIB Sensitivity of RUT and histology may be low in GIB Positive RUT or histology  H.P eradication Negative RUT or histology  UBT or FAT at later date

63 AGA recommendations in Uninvestigated Dyspepsia  In regions with high prevalence of H. pylori :  Antibody testing is good screening test  In regions with low prevalence of H. pylori:  Negative result is acceptable  Positive result should be confirmed with a UBT or FAT that identifies active infection

64 Testing to Prove H.P Eradication After Antibiotic Therapy 1.Any H. pylori-associated ulcer 2. Persistent dyspeptic symptoms despite the a course of H.P treatment 3.H. pylori-associated MALT lymphoma 4.Individuals who have undergone resection of early gastric cancer

65 Testing to Prove H.P Eradication After Antibiotic Therapy  If EGD is clinically indicated : Histology ± RUT RUT alone has low sensitivity in the post treatment setting and is not recommended  : If EGD is not indicated: UBT or FAT Anti H.pylori Ab is not recomended

66 Empirical H. Pylori eradication in PUD In region that prevalence of H.pylori in DU is more than 90% H. Pylori eradication can be started without any H. pylori test

67 Treatment of H. pylori Infection 1.Triple: PPI + Clarithro + Amoxi/Metro 14 day 2.Quadruple : PPI+ Bismuth + Metro +Tetra days 3. Sequential therapy :PPI + Amoxi (5 days)  PPI + Clarithro + Tinidazole (5 days)

68

69 Treatment of H. pylori Infection  PPI should be used b.i.d  H2RA can be substituted if a patient cannot tolerate PPI

70 Predictors of H. pylori Treatment Outcome  Most important predictors of failure are 1.Poor compliance 2.Antibiotic resistance.  There is limited evidence to suggest that smoking, alcohol, and diet may reduce successful eradication

71 Common side effects of drugs PPIheadache, diarrhea ClarithroGI upset, diarrhea, altered taste AmoxiGI upset, headache, diarrhea Metrometallic taste, dyspepsia TetracyclineGI upset, photosensitivity Bismuthdarkening of the tongue and stool, nausea, and GI upset

72 Antibiotic resistance Metronidazole:37% Clarithromycin:10% Both antibiotics:3.9% Amoxicillin :1.4%. Metronidazole resistance can be overcome by use of higher doses(500 mg tds)

73 Antibiotic resistance  Previous treatment with a macrolide or metronidazole for any reason significantly increase resistance  In patients with persistent H. pylori ; avoidance from previously used antibiotics is recomended

74 culture and antibiotic sensitivity  Are typically not performed unless a patient has failed at least 2 courses of therapy.  Even in this circumstance, the usefulness of such testing is arguable.

75 Recommendations in persistent infection  If patient has not been previously treated with clarithro, triple therapy can be done  Levofloxacin-based triple therapy for 10 days is another option (Levofloxacin 500mg daily+ Amoxi 1gr BD+PPI)  Other antibiotic used include Rifabutin and Furazolidone.

76 Maintenance antisecretory therapy  Is recommended in :  High-risk patient who fail H. pylori eradication  H. pylori-negative ulcers With: PPI or Cimetidine 400 mg / Ranitidine150 mg Famotidine20 mg / Nizatidine150 mg at bedtime

77 Maintenance antisecretory therapy  Uncomplicated recurrent disease; stopping therapy after two years  Complicated disease; five-year may be more appropriate

78 Maintenance antisecretory therapy  Rebound acid-hypersecretion is important following abrupt cessation of PPI stepping-down to low dose PPI and then to full dose H2RA is an appropriate caution

79 H. pylori negative ulcers  Special attention to ensure that H. pylori infection and NSAID has been excluded  In confirmed non-H. pylori, non-NSAID ulcers; excluding acid hypersecretory states, such as ZES (fasting serum Gastrin )

80 H. pylori test&treat in NSAID user  Before starting NSAIDs or aspirin (even at low dose), consider testing for H. pylori  In NSAID users with ulcer complications and evidence of H. pylori, curing H. pylori does not reduce high risk of ulcer complications if NSAIDs are continued.


Download ppt "Peptic ulcer disease. Disruption of mucosal and submucosal integrity of the stomach and/or duodenum >5 mm in size Definition."

Similar presentations


Ads by Google